Trial reportNature2017
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
6 registry-linked trialsOpen access · greenAbstract readClinical Trial
In one paragraph
Trial report in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 1,064 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,064citing papers in PubMed, 4 pooled it
76.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Volume and Dose De-Intensification Following Transoral Robotic Surgery (TORS) and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma
Phase II Study of Toripalimab (JS001) Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis
NCT04153734 phase2not yet recruitingnot on this mapstarted 2019, after this paper: background citation
Pembrolizumab + Platinum Doublets Without Radiation for Patients With PD-L1 ≥50% Locally Advanced Non-small Cell Lung Cancer: a Multicenter Prospective Single Arm Phase II Study
Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy
NCT07072325 phase1not yet recruitingnot on this mapstarted 2025, after this paper: background citation
A Clinical Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Head & Neck Cancers
Who cites it
1,064 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,620 citations in OpenAlex.
- Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2025Pooled it
- The Efficacy and Safety of Durvalumab and Tremelimumab with Concomitant Treatment for MSS/pMMR Metastatic Colorectal Cancer: A Single Arm Meta-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- The efficacy and immune-mediated safety of PD-1/PD-L1 combined with neoadjuvant chemotherapy in triple-negative breast cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.Nature communications · 2026Trial
- Trial
- Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.Cancer research communications · 2026Trial
- Efficacy of argon-helium cryoablation combined with PD-1 inhibitors in non-small cell lung cancer.Acta oncologica (Stockholm, Sweden) · 2025Trial
- Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.British journal of cancer · 2025Trial
- TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study.International journal of cancer · 2025Trial
- First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors.Cancer research communications · 2025Trial
- Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial.Nature cancer · 2025Trial
- Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.Nature communications · 2025Trial
- Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Cancer cell · 2024Trial
- Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial.Nature communications · 2024Trial
- Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Contrasting functions of CD73 and adenosine in CD8+ T-cell exhaustion during antitumor immunity.Oncoimmunology · 2026Article
- The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants.Cancer biology & therapy · 2026Review
- Using peripheral blood indicators and T cells subsets to evaluate the efficacy of immunotherapy for advanced and recurrent cervical cancer.Human vaccines & immunotherapeutics · 2026Article
1,004 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 4 institutions in 1 country.
Alexander C HuangDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michael A PostowDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Robert J OrlowskiDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Rosemarie MickAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Bertram BengschInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sasikanth ManneInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Wei XuDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Shannon HarmonDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Josephine R GilesInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Brandon WenzDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Matthew AdamowImmune Monitoring Facility, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Deborah KukDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Katherine S PanageasDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Cristina CarreraDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Phillip WongImmune Monitoring Facility, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Felix QuagliarelloInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Bradley WubbenhorstDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kurt D'AndreaDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kristen E PaukenInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ramin S HeratiDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ryan P StaupeInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jason M SchenkelDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Suzanne McGettiganDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Shawn KothariDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sangeeth M GeorgeInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Robert H VonderheideDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ravi K AmaravadiDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Giorgos C KarakousisAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Lynn M SchuchterDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Xiaowei XuAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Katherine L NathansonDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jedd D WolchokDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Tara C GangadharDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
E John WherryInstitute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
University of Pennsylvania · USMemorial Sloan Kettering Cancer Center · USParker Institute for Cancer Immunotherapy · USBrigham and Women's Hospital · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MUNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Susan M Domchek · 1985 to 2026
$222.3MVirology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F, WEERARATNA, ASHANI T · 2008 to 2023
$37.1MSynergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI E. John Wherry · 2015 to 2026
$30.8MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MInstitutional Clinical and Translational Science AwardKL2TR001879 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MEAGHER, EMMA ANNE · 2016 to 2025
$13.7MSequencing and Viral Evolution CoreU19AI117950 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D · 2015 to 2019
$12.0MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI SCHUCHTER, LYNN M. · 2014 to 2018
$11.1MCANCER RESEARCH TRAINING PROGRAMT32CA009615 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Gregory L Beatty, MICHAEL D HOGARTY · 1988 to 2026
$10.4MCellular and transcriptional control of exhausted CD8 T cells lineage dynamicsR01AI105343 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2014 to 2017
$1.6MEffects of aging on the T follicular helper response to influenza vaccineK08AI114852 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HERATI, RAMIN · 2015 to 2019
$947kNCATS NIH HHS KL2 TR001879NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016520NCI NIH HHS P50 CA174523NCI NIH HHS T32 CA009140NCI NIH HHS T32 CA009615NIAID NIH HHS K08 AI114852NIAID NIH HHS P01 AI108545NIAID NIH HHS R01 AI105343NIAID NIH HHS U19 AI082630NIAID NIH HHS U19 AI117950NIA NIH HHS F32 AG047773NIH HHS T32 2T32CA009615-26
Abstract
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical benefit. Pre-existing T-cell infiltration and/or the presence of PD-L1 in tumours may be used as indicators of clinical response; however, blood-based profiling to understand the mechanisms of PD-1 blockade has not been widely explored. Here we use immune profiling of peripheral blood from patients with stage IV melanoma before and after treatment with the PD-1-targeting antibody pembrolizumab and identify pharmacodynamic changes in circulating exhausted-phenotype CD8 T cells (T
Indexed as
Antibodies, Monoclonal, HumanizedCD8-Positive T-LymphocytesFemaleHumansKi-67 AntigenMaleMelanomaNeoplasm StagingPhenotypeProgrammed Cell Death 1 ReceptorTreatment OutcomeTumor BurdenAntibodies, Monoclonal, HumanizedKi-67 AntigenPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03729518ClinicalTrials.gov
NCT03927898ClinicalTrials.gov
NCT04153734ClinicalTrials.gov
NCT04262687ClinicalTrials.gov
NCT04707547ClinicalTrials.gov
NCT07072325ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.